Status:

UNKNOWN

Phase 2a Randomized, Double-Blind Study of Oleoyl-Estrone in Male Morbidly Obese Adults

Lead Sponsor:

Manhattan Pharmaceuticals

Conditions:

Obesity

Eligibility:

MALE

18-60 years

Phase:

PHASE2

Brief Summary

Multi-center, multiple-dose, randomized, double-blind, three-arm, placebo-controlled study of fixed-dose repeated oral dosing for 30 days of 10 mg and 30 mg MP-101 and placebo in obese subjects.

Eligibility Criteria

Inclusion

  • Subject is willing and able to provide signed informed consent.
  • Subject is a male and is between 18-60 years of age.
  • Subject is obese as defined as a BMI of 40 - 55.
  • Subject is reasonably healthy and have a reasonably acceptable medical history
  • Subject has a stable weight for the past 30 days per subject report.
  • Subject who has at least one factor of the metabolic
  • Subject exhibits stable behavior patterns with regard to smoking and exercise
  • Subject can read, speak and write the English language and agrees to follow study procedures.

Exclusion

  • Subjects who have received any investigational medication within 3 months prior to administration of study drug
  • Subjects with confirmed positive results of UDS or Alcohol
  • Subjects who are unwilling to return to the clinical research center on specified days during the treatment periods.
  • Subjects who have taken exclusionary medication
  • Subjects with any clinically significant laboratory abnormality or illness which, in the opinion of the Investigator, would contraindicate study participation
  • Subjects who have a history of testing positive for Hepatitis B virus, Hepatitis C virus, or HIV.
  • Subject has been involved in a formal or informal (self-imposed) diet regimen within the last 30 days.
  • Subject has a confirmed diagnosis or history of cancer, with the exception of nonmelanoma skin cancer.
  • Subject is otherwise unsuitable for the study, in the opinion of the investigator.

Key Trial Info

Start Date :

October 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT00449254

Start Date

October 1 2006

Last Update

June 5 2007

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

St. Luke's-Roosevelt Hospital

New York, New York, United States, 10025

2

Research Across America

Dallas, Texas, United States, 75234

3

Jean Brown Research

Salt Lake City, Utah, United States, 84124